Liquid Embolic Market Set for 9.0% CAGR Growth Through 2032, Persistence Market Research Reports

The global liquid embolic market is experiencing strong momentum as minimally invasive treatment modalities gain traction across neurology, oncology, and interventional radiology. According to a recent analysis by Persistence Market Research, the market is projected to rise from US$ 384.2 million in 2025 to US$ 703.6 million by 2032, expanding at a CAGR of 9.0% during the forecast period. This growth underscores the increasing adoption of embolic therapies for treating vascular abnormalities, brain aneurysms, and tumor embolization-driven by technological innovations and a rising incidence of chronic diseases globally.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/25513

Overview of the Market

Liquid embolic agents are polymer-based or adhesive substances injected into blood vessels to block abnormal blood flow, control bleeding, or deprive tumors of oxygenated blood. These agents have become essential tools in neurovascular and peripheral interventions, providing clinicians with a minimally invasive alternative to open surgeries. Initially used primarily for arteriovenous malformations (AVMs), their application has expanded to aneurysm treatments, tumor embolization, and hemorrhage management.

From 2019 to 2024, the market grew at a robust 8.0% CAGR, reflecting the widespread adoption of interventional radiology techniques. This upward trajectory is expected to continue, driven by the rising prevalence of neurological disorders, advancements in delivery systems, and increasing demand for minimally invasive procedures that reduce hospital stays and post-operative complications.

The neurovascular segment-particularly the treatment of brain aneurysms-currently dominates the market, accounting for more than 56% of total revenue in 2025. This dominance is attributed to the growing burden of cerebrovascular diseases and improvements in embolic precision technologies. Regionally, North America leads the global market, capturing approximately 61.3% of the total share, fueled by high adoption rates of advanced embolization technologies, robust healthcare infrastructure, and continuous innovation from leading medical device manufacturers.

Key Highlights from the Report

• Rising global cancer incidence, particularly in the liver and kidneys, is driving embolotherapy demand.
• Technological advancements are improving precision and treatment outcomes in embolic procedures.
• Neurovascular applications remain the dominant treatment area within the liquid embolic market.
• North America continues to lead globally due to advanced healthcare systems and early technology adoption.
• Asia Pacific is emerging as the fastest-growing regional market, supported by medical tourism and healthcare investments.
• Increased R&D and regulatory approvals are expanding the use of liquid embolic agents beyond neurointervention.

Market Segmentation

The liquid embolic market can be categorized based on product type, indication, and end-user, each contributing distinctly to overall market performance.

By Product Type:
The liquid embolic vials segment holds the largest market share, representing around 80.2% of total revenue in 2025. Their dominance is attributed to the ease of use in high-volume treatments, efficient packaging, and improved storage benefits. Products such as Onyx 34L LES, offered in recyclable packaging, further support sustainability goals and cost efficiency. These vials are preferred by hospitals and interventional centers for their consistent dosing and simplified workflow, making them a cornerstone product for embolization therapies.

By Indication:
Within indications, brain aneurysms remain the leading category with a 56.4% share in 2025. Aneurysm embolization is increasingly preferred over surgical clipping due to its minimally invasive nature and lower recovery time. The growing incidence of aneurysms, along with expanding indications for complex and wide-neck aneurysms, underscores the importance of liquid embolics in neurovascular care. Other significant applications include brain arteriovenous malformations (bAVMs) and dural arteriovenous fistulas (dAVFs)-each demanding precision and control achievable through liquid embolic agents.

By End-User:
Hospitals dominate the end-user segment, accounting for 58.3% of market value in 2025. The high patient volume for neurovascular and oncology procedures, coupled with better access to advanced imaging and catheterization facilities, drives this segment. Moreover, the integration of interventional radiology units within hospital settings allows for immediate response to vascular emergencies, further boosting adoption. Ambulatory surgical centers (ASCs) and specialized neurointerventional clinics are also expanding their role as healthcare shifts toward outpatient care models.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/liquid-embolic-market.asp

Regional Insights
North America

North America is the leading regional market, capturing more than 61% of global revenue in 2025. The region benefits from a robust healthcare infrastructure, early technology adoption, and the presence of key industry players such as Medtronic and Cerenovus. Rising incidences of neurovascular diseases and increased preference for minimally invasive embolization procedures have amplified product demand. Furthermore, the proliferation of ambulatory surgical centers (ASCs) specializing in neurointerventions enhances patient access and operational efficiency. Government support for medical device innovation also fosters a favorable environment for market growth.

Europe

Europe represents the second-largest market, holding nearly 21% of the global share with an estimated CAGR of 8.6% through 2032. Countries such as Germany, France, and the U.K. lead due to extensive clinical research networks and high procedural volumes. Germany, in particular, hosts over 50 active research ethics committees focused on medical and cancer studies, reflecting a strong culture of innovation. The European Union's emphasis on research-driven healthcare solutions and clinical validation ensures a consistent pipeline of advanced embolic systems entering the market.

Asia Pacific

The Asia Pacific region is expected to grow at the fastest CAGR of 10.6% during the forecast period. Rapid urbanization, increasing healthcare expenditure, and rising awareness about minimally invasive therapies drive demand in countries such as China, India, Japan, and South Korea. The region faces a significant burden of neurological and cardiovascular disorders, with China alone accounting for nearly 7% prevalence of unruptured cerebral aneurysms among adults. Additionally, the growth of medical tourism in Southeast Asia and increased private investment in hospital infrastructure are key contributors to market expansion.

Market Drivers

The most significant driver for the liquid embolic market is the growing demand for minimally invasive procedures in oncology and neurology. Embolization allows physicians to block blood flow to tumors, manage hemorrhages, or occlude abnormal vascular networks without major surgery. Rising cases of liver, kidney, and brain tumors-often in patients unfit for open surgery-have accelerated the use of embolization. Furthermore, technological advancements in catheter design, delivery precision, and polymer stability have made procedures safer and more effective.

Additionally, the aging population and associated increase in chronic diseases such as cancer and aneurysms contribute to long-term demand. Healthcare providers increasingly prefer embolic agents due to shorter recovery times, reduced hospitalization costs, and lower postoperative risks. Continuous R&D aimed at developing next-generation bioadhesive and radiopaque embolic formulations further propels market growth.

Market Restraints

Despite strong growth prospects, the liquid embolic market faces challenges related to technical complexity and procedural risks. Precise embolic delivery requires advanced imaging systems and skilled interventional radiologists-resources not equally available across all healthcare settings. Misplacement or non-target embolization can lead to severe complications such as tissue necrosis or neurological damage, deterring widespread adoption.

Moreover, the market's growth is constrained by stringent regulatory frameworks and the limited number of manufacturers capable of producing clinically approved embolic agents. High development costs, coupled with competition from other embolic modalities (like coils and microspheres), create barriers for new entrants. The need for extensive clinical validation further slows down innovation and market penetration.

Market Opportunities

Significant opportunities lie in the expanding applications of liquid embolic agents beyond neurointerventional procedures. The rising global incidence of cancer-estimated by GLOBOCAN at nearly 20 million new cases in 2022-creates vast potential for tumor embolization therapies. These procedures can directly target tumor-feeding arteries, offering a minimally invasive, localized treatment alternative.

Emerging economies in Asia Pacific and Latin America present attractive opportunities for market expansion due to improving healthcare infrastructure and increasing access to interventional radiology. Additionally, regulatory approvals for new indications, such as peripheral vascular hemorrhage, open new commercial avenues for manufacturers. Companies focusing on product differentiation, training programs, and collaborations with hospitals are likely to secure a competitive edge in these high-growth regions.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/25513

Company Insights

Key players in the global liquid embolic market include several major medical device manufacturers and emerging innovators, each contributing to product advancement and market expansion.

• Cerenovus (Johnson & Johnson)
• Medtronic
• Sirtex Medical Inc.
• Terumo Neuro
• Balt
• Meril Life Sciences Pvt. Ltd.
• INVAMED
• Peters Surgical

Market Segmentation

By Product

Liquid Embolic Vials
Prefilled Injectables

By Indication

Brain Arterio-Venous Malformations (bAVM)
Tumor Embolization
Brain Aneurysm
Dural Arteriovenous Fistulas (dAVFs)
Others

By End-user

Hospitals
Ambulatory Surgical Centers
Independent Speciality Centres
Others

By Region:

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East & Africa

Recent Developments:

In March 2024, Cerenovus Inc. launched the TRUFILLTM n-BCA Liquid Embolic System Procedural Set, enhancing procedural efficiency for hemorrhagic stroke treatment.

In November 2023, Sirtex Medical introduced the LAVA Liquid Embolic System, the first liquid embolic agent specifically approved for treating peripheral vascular hemorrhage.

These developments underscore the industry's focus on innovation, precision, and safety in embolic therapy. Strategic collaborations, R&D investment, and targeted regulatory strategies remain key competitive differentiators.

Conclusion

The liquid embolic market is poised for sustained growth through 2032, underpinned by rising global incidences of cancer and neurovascular disorders, increasing demand for minimally invasive interventions, and steady technological innovation. While North America continues to dominate due to its mature healthcare infrastructure, emerging markets in Asia Pacific are rapidly catching up, driven by expanding access to advanced care and an increasing number of trained specialists.

Challenges such as procedural complexity and regulatory barriers remain, but continuous R&D and product diversification are expected to mitigate these risks. As manufacturers pursue broader indications and leverage material science innovations, the liquid embolic market is likely to evolve into one of the most dynamic segments in interventional medicine-offering safer, faster, and more effective treatment pathways for patients worldwide.

Read More Related Reports:

Advanced Medical Nutrition Market https://www.persistencemarketresearch.com/market-research/advanced-medical-nutrition-market.asp
Dysphagia Supplements Market https://www.persistencemarketresearch.com/market-research/dysphagia-supplements-market.asp
Human Platelet Lysate Market https://www.persistencemarketresearch.com/market-research/human-platelet-lysate-market.asp
Cleanroom Disinfectant Market https://www.persistencemarketresearch.com/market-research/cleanroom-disinfectant-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.